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NeLFe-Dependent MYC signature 
Identifies a Unique Cancer Subtype 
in Hepatocellular Carcinoma
Hien Dang1,4, Yotsawat Pomyen  1,3, Sean P. Martin  1, Dana A. Dominguez1, 
sun Young Yim2, Ju-Seog Lee2, Anuradha Budhu1, Ashesh P. Shah5, Adam S. Bodzin5 & 
Xin Wei Wang  1
The MYC oncogene is dysregulated in approximately 30% of liver cancer. In an effort to exploit MYC as 
a therapeutic target, including in hepatocellular carcinoma (HCC), strategies have been developed on 
the basis of MYC amplification or gene translocation. Due to the failure of these strategies to provide 
accurate diagnostics and prognostic value, we have developed a Negative Elongation Factor E (NELFE)-
Dependent MYC Target (NDMT) gene signature. This signature, which consists of genes regulated 
by MYC and NELFE, an RNA binding protein that enhances MYC-induced hepatocarcinogenesis, is 
predictive of NELFE/MYC-driven tumors that would otherwise not be identified by gene amplification 
or translocation alone. We demonstrate the utility of the NDMT gene signature to predict a unique 
subtype of HCC, which is associated with a poor prognosis in three independent cohorts encompassing 
diverse etiologies, demographics, and viral status. The application of gene signatures, such as the 
NDMT signature, offers patients access to personalized risk assessments, which may be utilized to 
direct future care.
Hepatocarcinogenesis is a complex process associated with numerous changes at both the genetic and epige-
netic levels. The activation of oncogenes and dysregulation of signal transduction pathways, such as Negative 
Elongation Factor E (NELFE)/MYC, Wnt/β-catenin, hepatocyte growth factor (HGF)/c-Met, and transforming 
growth factor β (TGFβ) all contribute to hepatocarcinogenesis1. One common change found in many cancers, 
including hepatocellular carcinoma (HCC), is the alteration of the MYC oncogene2. MYC regulates more than 
15% of the transcriptome, controlling cellular processes such as proliferation, differentiation, apoptosis and met-
abolic programming2. MYC amplification is the most common alteration in cancers and is often used as a bio-
marker. Additionally, dysregulated MYC signaling without gene amplification, mutation or translocation is also 
observed3. The complex nature of MYC alteration is a potential rationale as to why some MYC targeted therapies 
fail4. Since MYC and its network are altered by complex mechanisms, characterization of the MYC gene copy 
number or translocation alone is not sufficient to identify MYC-driven tumors. The present study seeks to evalu-
ate a gene signature to predict MYC-driven tumors in HCC.
We have previously demonstrated that the activation of NELFE enhances MYC-induced hepatocarcinogen-
esis by supporting the tumor transcriptome5. Our findings suggest NELFE promotes hepatocarcinogenesis by 
either regulating the stability of downstream MYC targets or by directly interacting with the MYC protein to 
enhance transcription. Furthermore, we identified a subset of oncogenic MYC targets regulated by NELFE, called 
NELFE-dependent MYC targets (NDMTs), in HCC tumor tissue and have functionally validated these findings 
through in vitro studies. While the NELFE/MYC axis may be a potential therapeutic target, there are currently no 
NELFE directed therapies. Historically, MYC has been considered an undruggable target due to its complex role 
in the cell6. Despite this preconception, attempts to target MYC have been made by identifying tumors in which 
MYC is overexpressed6,7. This approach, however, does not address tumors that may be driven by NELFE/MYC 
dysregulation whereby MYC overexpression is not required to drive MYC-induced tumorigenesis2,5,6.
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HCC is the second most common cause of cancer related deaths worldwide8. The incidence of HCC continues 
to rise in the United States, where the overwhelming majority of patients are diagnosed with advanced disease. 
As such, most patients are deemed non-surgical candidates, eliminating curative therapeutic options. Despite 
considerable efforts toward improving diagnosis, progress in durable treatment options have remained elusive, 
most offering minimal improvement in survival. Due to these challenges, HCC remains among the most difficult 
to treat malignancies with a 5-year survival of less than 15% in the United States8. The array of underlying liver 
diseases associated with HCC, heterogeneity of the tumor, advanced disease at presentation, ineffective chemo-
therapy, and high recurrence rates all contribute to the overall poor prognosis of HCC8,9. With the current para-
digm offering patients very little, a strategy to stratify HCC subtypes according to their tumor biology is needed to 
improve therapeutic response. In the current study, we establish an NDMT gene signature composed of 20 genes 
regulated by NELFE/MYC with the goal of identifying a unique subtype associated with poor survival in HCC.
Results
Establishment of the NELFE Dependent MYC Target (NDMT) gene signature. We previously 
demonstrated that the oncogenic RNA binding protein (RBP) NELFE supports the tumor transcriptome by reg-
ulating MYC and its targets5. Furthermore, we identified 68 oncogenic NELFE/MYC target genes associated 
with poor survival and demonstrated that in HCC, patients with elevated NELFE gene expression have a poor 
prognosis5. To further establish a robust gene signature, we filtered genes with least 1.5-fold change (tumor vs. 
non-tumor) from the 68-gene list, which resulted in 20 genes (Fig. 1A, Supplementary Fig. S1). To establish the 
signature’s prognostic index, we performed survival risk prediction analysis using the Liver Cancer Institute (LCI) 
cohort (see Methods) (GSE14520)10,11. Briefly, the algorithm uses all 20 genes and fits them into a Cox propor-
tional hazards model to provide an assessment of whether the association of each gene expression to survival data 
is statistically significant12. Accordingly, the NDMT gene signature stratified patients with a significant difference 
in overall survival (OS) (Fig. 1B). The subgroup of patients with attenuated survival is referred to as NDMTs, 
while those with favorable survival are henceforth referred to as Non-NDMTs. The NDMT subtype had a median 
survival of only 37.9 months compared to the Non-NDMT subtype, which did not yet reach the median survival 
by the end of data collection (Log rank p < 0.0001). The molecular signature’s cross-validated misclassification 
rate was significantly lower than by random chance (permutation p = 0.002) (Fig. 1B). In addition, principal 
components analysis using the NDMT gene expression in the LCI cohort further confirmed the existence of two 
distinct tumor types (Fig. 1C).
We next performed a multivariate Cox proportional hazards regression analysis (Table 1) comprised of 
univariate variables with a p < 0.05, which included the NDMT signature status, stage, cirrhosis status and 
alpha-feto protein (AFP) levels of >400 ng/ml. Both tumor size and microvascular invasion, which were sig-
nificant in the univariate analysis, were excluded due to collinearity (Table 1). The NDMT prognostic signature 
was an independent predictor of OS with a hazard ratio (HR) of 1.8 (95% CI = 1.1–2.9, p = 0.010). In addition, 
we ran our analysis for both the Barcelona-Clinic Liver Cancer (BCLC) and TNM Classification of Malignant 
Tumors (TNM) staging, which were found to be significant (TNM: HR = 1.8, 95% CI = 1.8–4.8 p < 0.001, BCLC: 
HR = 3.0, 95% CI 1.9–4.7, p < 0.001). Neither AFP nor cirrhosis status were found to be significant.
Validation of the NDMT signature in other HCC cohorts. Next, we tested the gene signature in 
three independent HCC cohorts (Supplementary Table 1). Accordingly, the Laboratory of Experimental 
Carcinogenesis (LEC) cohort (GSE1898 and GSE4024) (n = 139) consists of patients of European background 
who are HBV/HCV positive, the Korean (KOR) cohort (GSE15765) (n = 158) consists mostly of HBV positive 
patients, and The Cancer Genome Atlas-Liver Hepatocellular Carcinoma (TCGA-LIHC) cohort (n = 364) con-
sists of Asian, African, Hispanic and Caucasian patients who are HBV/HCV positive13–16. Kaplan-Meier log rank 
analyses were performed to assess the relationship between the NDMT subtype and OS. In the LEC cohort, the 
Non-NDMT subtype experienced a median survival of 43.8 months compared to 14.0 months in the NDMT sub-
type (p = 0.007). In the TCGA-LIHC cohort, the median survival of Non-NDMTs were 104.2 months compared 
to 33.5 months in NDMTs (p < 0.001). Finally, in the Korean cohort, the NDMT subtype’s median survival was 57 
months, whereas at the end of data collection, the Non-NDMT subtype had yet to be defined (p = 0.027). Of note, 
the median OS in the LEC cohort is significantly shorter than the LCI, TCGA-LIHC or the Korean cohort, which 
is consistent with the late stage disease observed at diagnosis. Together, these data suggest the gene signature is 
a predictor of poor survival and is robust in predicting the NDMT subtype among different HCC cohorts across 
various races/ethnicities and mixed etiology.
To test whether the gene signature is independent of other prognostic factors, including sex, age, cirrhosis 
status, AFP, TNM staging, BCLC staging, and BMI in the validation cohorts, we performed Cox regression anal-
ysis in the LEC, TCGA-LIHC and the Korean datasets (Table 2). Univariate Cox regression analyses revealed 
the NDMT signature was a significant predictor of survival in the TCGA-LIHC (HR = 2.9, 95% CI = 1.8–4.8, 
p < 0.001), LEC (HR = 1.9, 95% CI = 1.1–3.1, p = 0.015), and Korean (HR = 2.3, 95% CI = 1.1–5.1, p = 0.035) 
cohorts. In the TCGA-LIHC cohort, TNM stage (HR = 2.1, 95% CI = 1.3–3.6, p = 0.005) and BCLC staging 
(HR = 3.1, 95% CI = 1.5–6.3, p = 0.002) were also significant predictors of survival (Table 2). In addition to 
the NDMT signature, microvascular invasion status (HR = 3.2, 95% CI = 1.5–6.9, p = 0.003) and TNM staging 
(HR = 2.2, 95% CI = 1.0–4.8, p = 0.046) were also predictive of OS in the Korean cohort. The NDMT signature 
was the only significant predictor of survival in the LEC and thus, no further multivariate analysis was performed 
(Table 2).
We next performed multivariate Cox regression analysis between the NDMT signature and significant pre-
dictors from the univariate analyses to investigate their relationship. In the TCGA-LIHC dataset, the NDMT 
signature remained an independent predictor of survival (HR = 2.6, 95% CI = 1.3–5.1, p = 0.005) along with 
BCLC staging (HR = 3.1, 95% CI = 1.5–6.3, p = 0.002) (Table 2). In addition, we also investigated TNM staging 
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independently from BCLC as both staging systems consist of similar parameters, including tumor size and lymph 
node invasion. We found that the 20-NDMT signature (HR = 2.6, 95% CI = 1.5–4.5, p < 0.001) remained inde-
pendent when using TNM staging (HR = 2.1, 95% CI = 1.2–3.5, p = 0.006) (Table 2), indicating its prognostic 
value. Notably, the number of available data points in the LEC and Korean datasets for the analyzed clinical 
factors in the NDMT subtype are small, which may not be adequate to draw any conclusions (See Supplementary 
Table 1).
Performance of the NDMT signature. To determine the signature’s potential use in the clinical setting, 
we performed time-dependent receiver operating characteristic (ROC) curve analyses on three of the four HCC 
cohorts with a cut-off at 2-years based on the finding that the 5-year survival rate is less than 15%. We elected 
to not analyze the Korean cohort due to lack of sufficient gene expression data for all samples. In addition, we 
compared our NDMT gene signature to six other known gene signatures including the Andersen signature17, 
Roessler Metastasis signature10, Hoshida signature18,19, Lee signature13, and Yamashita’s EpCAM signature20. In 
the LCI cohort, ROC analyses indicated the gene signature had the best predictive accuracy (area under the curve 
Figure 1. Development of the 20-NELFE Dependent MYC Target (20-NDMT) signature. (A) The work flow 
of the study from establishing the NDMT signature to validation in HCC cohorts and other tumor types. (B) 
Survival risk prediction analysis using the Liver Cancer Initiative (LCI) cohort. P values displayed are calculated 
by Mantel-Cox log-rank test and permutation test with 10-fold cross validation. (C) Principal component 
analysis (PCA) of the LCI cohort using only the 20 genes from the signature (PC: principal component). (D) 
Kaplan-Meier analysis of three independent HCC cohorts. P-values are from Mantel-Cox log-rank test in the 
Laboratory of Experimental Carcinogenesis (LEC), Korean (KOR) cohort, and The Cancer Genome Atlas-Liver 
Hepatocellular Carcinoma (TCGA-LIHC).
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(AUC) = 0.69) compared to other published gene signatures (Fig. 2A). In the TCGA-LIHC and the LEC cohort, 
ROC curve analyses indicated the NDMT gene signature performed as well as other signatures and demon-
strated acceptable predictive accuracy (AUC = 0.62 for TCGA-LIHC and AUC = 0.62 for LEC) (Supplementary 
Fig. S2A,B). However, the NDMT signature was outperformed by the Hoshida S3 signature in the TCGA-LIHC 
(AUC = 0.68) cohort and the Lee signature (AUC of 0.75) in the LEC cohort (Supplementary Fig. S2B). Together, 
these findings indicate that the NDMT signature identifies a very specific HCC subtype with NELFE/MYC sign-
aling and its performance is stable across unique etiologies.
Clinical decisions are often guided by AFP and BCLC staging, both of which were independent predic-
tors of OS in the LCI and TCGA-LIHC cohorts. Thus, we tested whether AFP levels or BCLC staging could 
improve the prognostic prediction of the NDMT signature. For AFP, we divided patients into subgroups based 
on a cutoff of 400 ng/ml, resulting in three groups: >400/NDMTs, <400/Non-NDMTs, or Discordant (patients 
with no correlation). Kaplan-Meier curve analyses in the LCI cohort showed that patients in the Non-NDMT 
subtype with AFP levels of <400 ng/ml had a significantly better OS than patients in the NDMT subtype with 
AFP levels >400 ng/ml (p = 0.0001). This finding was also observed in the TCGA-LIHC cohort (Fig. 2B (left), 
Supplementary Fig. S2C). Patients with AFP levels >400 ng/ml in the NDMT HCC subgroup had a median sur-
vival of 36.4 months in the LCI cohort and 33.5 months for TCGA-LIHC, whereas at the end of data collection, 
patients in the Non-NDMT subgroup with AFP levels <400 ng/ml or the Discordant group had yet to be defined 
in the LCI cohort (Supplementary Fig. S2C, left). In the TCGA-LIHC cohort, patients with AFP levels <400 ng/
ml in the Non-NDMTs group had a median survival of 104.2 months and the Discordant group had a median of 
45.7 months (Supplementary Fig. S2C, right). For BCLC staging, we stratified patients with BCLC stage 0 and A 
into A&0, BCLC stage B and C into B&C groups, which resulted into three distinct groups: A&0/Non-NDMTs, 
B&C/NDMTs, or Discordant. Survival analyses in both cohorts showed that NDMT patients with BCLC stages 
B&C had a worse OS compared to Non-NDMT patients with BCLC A&0 or the Discordant (p < 0.0001) group 
with a median survival of 19.2 months and 33.5 months for the LCI and TCGA-LIHC, respectively (Fig. 2B, 
Supplementary Fig. S2C, right). At the end of data collection, the median survival for the Non-NDMT sub-
type with BCLC staging A&0 had yet to be defined for both cohorts, whereas the median survival for NDMTs 
with BCLC staging B&C had a median survival of 59.2 months and 84.7 months for LCI and TCGA-LIHC, 
Clinical variable Hazard Ratio (95% CI) p valuea
Univariate Analysis
20-NDMT Signature (NDMTs vs. Non-NDMTs) 2.3 (1.5–3.5) <0.001
Sex (Male vs. Female) 1.8 (0.9–3.7) 0.111
Age, y (≥50 vs <50) 0.8 (0.5–1.2) 0.268
Cirrhosis (Yes vs No) 4.8 (1.2–20.2) 0.025
BMI (≥24 vs <18.5) 0.7 (0.3–2.1) 0.565
HBV status (AVR-CC vs CC) 1.4 (0.9–2.2) 0.153
Child-Pugh class (B vs A) 1.4 (0.8–2.5) 0.247
ALT (≥50 vs <50) 1.2 (0.8–1.8) 0.370
AFP (>400 ng/ml vs ≤400 ng/ml) 1.7 (1.1–2.6) 0.009
Tumor size (>3 cm vs ≤3 cm) 2.5 (1.5–4.3) <0.001
Histological grade (II-IV vs. I) 0.9 (0.4–2.2) 0.914
Multinodular tumor (Yes vs No) 1.6 (1.0–2.4) 0.052
Microvascular invasion (Yes vs No) 1.7 (1.1–2.6) 0.009
BCLC staging (B&C vs A) 3.7 (2.4–5.8) <0.001
TNM staging (II + III vs I) 2.9 (1.8–4.8) <0.001
Multivariate Analysisb
20-NDMT Signature (NDMTs vs. Non-NDMTs) 1.8 (1.1–2.9) 0.010
Cirrhosis (Yes vs No) 3.4(0.8–13.9) 0.091
AFP (>400 ng/ml vs ≤400 ng/ml) 1.2 (0.8–2.1) 0.367
BCLC staging (B&C vs A) 3.0 (1.9–4.7) <0.001
Multivariate Analysisc
20-NDMT Signature (NDMTs vs. Non-NDMTs) 1.9 (1.2–3.0) 0.010
Cirrhosis (Yes vs No) 3.0 (0.7–12.5) 0.211
AFP ( > 400 ng/ml vs ≤ 400 ng/ml) 1.4 (0.9–2.2) 0.581
TNM staging (II + III vs I) 2.4 (1.4–3.9) 0.001
Table 1. Univariate and multivariate Cox regression analyses of the LCI cohort (n = 241). Note: Bold indicates 
significant p values. Abbreviations: AVR-CC, active viral replication chronic carrier; CC, chronic carrier; AFP-
alpha-fetoprotein; ALT, alanine aminotransferase; BCLC, Barcelona clinic liver cancer; BMI, body mass index; 
NA, not available. aUnivariate analysis. bMultivariate analysis, Cox proportional hazards regression adjusting for 
Cirrhosis, AFP status, and BCLC staging. cMultivariate analysis, Cox proportional hazards regression adjusting 
for Cirrhosis, AFP status, and TNM staging.
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respectively. Together, these data indicate that patients in the NDMT subtype are likely to have high levels of AFP 
and BCLC staging B or C and only BCLC staging status may improve the NDMT’s survival predictive accuracy.
To test whether AFP levels or BCLC staging improves the OS predictive accuracy of the NDMT signature, we 
performed two-year dependent ROC curve analyses for both cohorts. We found that the NMDT signature had 
no effect on AFP for both the LCI (AUC of AFP = 0.62, AUC of AFP + NDMTs = 0.67) and TCGA-LIHC cohorts 
(AUC of AFP = 0.55, AUC of AFP + NDMTs = 0.54) (Fig. 2C, Supplementary Fig. 2C). However, in the LCI 
cohort, the NDMT signature improved OS prediction for patients with BCLC B&C stages (AUC of BCLC = 0.67, 
AUC or BCLC + NDMTs = 0.75) (Fig. 2C). This finding was not observed in the TCGA-LIHC cohort (AUC of 
BCLC = 0.55, AUC of BCLC + NDMTs = 0.55), which may be due to the smaller sample size (Supplementary 
Fig. 2C). These data indicate that the NDMTs subtype is more likely to consist of HCC patients with advanced 
disease, i.e. patients with BCLC staging B or C.
NDMTs are associated with aggressive tumor types. We next assessed the gene signature’s predic-
tive ability on disease-free survival (DFS) by performing log-rank analyses in two HCC cohorts, the LCI and 
Korean cohorts. Log-rank analyses revealed the NDMT subtype had an earlier time to progression than the 
Non-NDMT subtype in the LCI (p = 0.015) and Korean (p = 0.007) cohorts (Fig. 2D). While the NDMT subtype 
in the LCI and Korean cohort had a median recurrence of 19.1 and 20 months, the Non-NDMT subtype had a 
median recurrence of 36.9 and 54.6 months, respectively. Univariate Cox proportional hazards analyses revealed 
the NDMT signature (HR = 1.5, 95% CI = 1.1–2.1, p = 0.020), cirrhosis status (HR = 2.7, 95% CI = 1.3–5.7, 
p = 0.011), microinvasion (HR = 1.4, 95% CI = 1.0–1.9, p = 0.040) and BCLC stage (HR = 2.3, 95% CI = 1.6–3.3, 
p < 0.001) were also predictive of DFS. Consistent with previous work, multivariate Cox regression analyses 
revealed that BCLC stage (HR = 2.7, 95% CI = 1.6–4.4, p < 0.001) and cirrhosis status (HR = 2.6, 95% CI = 1.1–
5.9, p = 0.024) remained independent predictors of DFS. The NDMT signature (HR = 2.3, 95% CI = 1.1–5.1, 
p = 0.035), microinvasion (HR = 3.2, 95% CI = 1.5–6.9, p = 0.003) and TNM stage (HR = 2.2, 95% CI = 1.0–4.8, 
p = 0.046) were also predictive of DFS. However, when we performed multivariate Cox regression analyses using 
only significant variables found in the univariate analyses, we observed that the 20-NDMT gene signature was no 
longer an independent predictor of DFS in both cohorts.
In addition to DFS and OS, the NDMT signature was evaluated as a predictor of aggressive tumor features. 
Using patient data from the LCI cohort, a variety of clinical factors were evaluated, including age, sex, viral status, 
stage at presentation, local tumor features and preoperative AFP. Univariate analysis showed that NDMT signa-
ture was associated with poor prognostic features such as size >5 cm (odds ratio (OR) = 2.26, 95% CI = 1.31–
3.77), microvascular invasion (OR = 2.12, 95% CI = 1.19–3.77), and local invasion into surrounding tissue 
(OR = 3.01, 95% CI = 1.05–8.66) (Fig. 2E). Additionally, the NDMT gene signature identified patients that were 
more likely to be diagnosed with BCLC stage B and C (OR = 2.32, 95% CI = 1.01–5.32) and elevated preoperative 
AFP (OR = 2.14, 95% CI = 1.27–3.60) (Fig. 2E). These findings suggest that the NDMT subtype consists of an 
aggressive form of HCC and the NDMT signature may aid in prognosis and help guide treatment and surveillance 
decisions beyond the current standard.
Clinical variable HR (95% CI) p valuea HR (95% CI) p valuea HR (95% CI) p valuea
Univariate Analysis TCGA-LIHC LEC KOREAN
20-NDMT Signature (NDMTs vs. Non-NDMTs) 2.9 (1.8–4.8) <0.001 1.9 (1.1–3.1) 0.015 2.3 (1.1–5.1) 0.035
Sex (Male vs. Female) 0.7 (0.5–1.2) 0.225 1.4 (0.8–2.3) 0.227 1.1 (0.4–2.9) 0.828
Age, years (≥50 vs <50) 1.2 (0.6–2.2) 0.582 0.7 (0.4–1.1) 0.148 0.9 (0.4–2.0) 0.726
Cirrhosis (Yes vs No) 0.8 (0.4–1.7) 0.535 1.4 (0.9–2.2) 0.191 2.3 (0.8–6.4) 0.128
AFP (>400 ng/ml vs ≤400 ng/ml) 1.1 (0.6–2.0) 0.836 1.4 (0.9–2.4) 0.161 1.3 (0.6–2.9) 0.501
Microvascular invasion (Yes vs No) 1.3 (0.8–2.2) 0.334 1.4 (0.6–3.3) 0.398 3.2 (1.5–6.9) 0.003
TNM staging (II + III vs I) 2.1 (1.3–3.6) 0.005 NA NA 2.2 (1.0–4.8) 0.046
BCLC Staging (B&C vs A) 3.1 (1.5–6.3) 0.002 0.7 (0.2–2.9) 0.595 2.0 (0.7–5.5) 0.167
Tumor size (>3 cm vs ≤3 cm) NA NA 1.5 (0.7–3.2) 0.329 1.8 (0.7–4.7) 0.233
Histological grade (II-IV vs I) 1.1 (0.5–2.3) 0.790 0.5 (0.1–2.0) 0.322 NA NA
Child-Pugh class (B vs A) 2.1 (0.9–5.1) 0.101 NA NA NA NA
Multivariate Analysisb
20-NDMT Signature (NDMTs vs. Non-NDMTs) 2.6 (1.3–5.1) 0.005
BCLC staging (B&C vs A) 3.1 (1.5–6.3) 0.002
Multivariate Analysisc
20-NDMT Signature (NDMTs vs. Non-NDMTs) 2.6 (1.5–4.5) p < 0.001
TNM staging (II + III vs I) 2.1 (1.2–3.5) 0.006
Table 2. Univariate and multivariate Cox regression analyses of the TCGA-LIHC, LEC, and KOREAN 
cohorts. Note: Bold indicates significant p values. Abbreviations: AFP, alpha-fetoprotein; ALT, alanine 
aminotransferase; BCLC, Barcelona clinic liver cancer; BMI, body mass index; NA, not available. aUnivariate 
analyses. bMultivariate analysis, Cox proportional hazards regression for Cirrhosis, AFP status, and BCLC 
staging. cMultivariate analysis, Cox proportional hazards regression adjusting for Cirrhosis, AFP status, and 
TNM staging.
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Genomic characteristics of the NDMT subtype. We next investigated the functional characteristics 
of the NDMTs with other known HCC subtypes using a nearest template prediction algorithm in the LCI coh
ort10,13,17,20–23. We found that the NDMT subtype consists of HCC with stem-like features as evident by the enrich-
ment of patients with Hepatoblastoma-like features and EpCAM (Fig. 3A). In addition, NDMTs were enriched 
with patients with metastatic and MYC alterations as identified by Hoshida’s S2 subtype (Fig. 3A)10.
To further confirm that NDMTs are enriched with active NELFE/MYC signaling, we performed differen-
tial gene expression analyses. First, we identified differentially expressed genes (DEGs) between the NDMT and 
Non-NDMT subtypes (two-sample t-test, p < 0.001) in the LCI (1,875 DEGs) and TCGA-LIHC cohort (5,281 
DEGs). From the two genes lists, we filtered out genes that are up-regulated or down-regulated in both gene 
lists, resulting in 1,104 DEGs. We then performed gene set enrichment analyses (GSEA) and ENCyclopedia Of 
DNA Elements (ENCODE) analyses to identify signaling pathways. Consistently, MYC signaling was signifi-
cantly enriched (Fig. 3B) in GSEA analyses. In addition, ENCODE analyses further confirmed that a significant 
number of the DEGs between NDMTs and Non-NDMTs were downstream targets of MYC and its partners, 
MAX and MXI1 (Fig. 3B, right). To confirm that the DEGs between NDMTs and Non-NDMTs were enriched 
with NELFE/MYC targets, we analyzed DEGs (Benjamin-Hochberg test, false discovery rate of <0.05) in the 
LCI or TCGA-LIHC cohort separately. We found a significant number of NELFE/MYC targets in the LCI cohort 
(hypergeometric test, p = 6.5 × 10−63) and the TCGA-LIHC cohort (hypergeometric test, p < 0.001) (Fig. 3C, 
Supplementary Fig. S3A), suggesting that the NDMT HCC subtype consists of active NELFE/MYC signaling.
Figure 2. The NDMT subtype is associated with agressive tumors. (A) (Left) Receiver operating curve (ROC) 
analyses of different gene signatures compared to the NDMT signature in the LCI cohort at two-year time-
points. (Right) Forest plot of the area under the curve (AUC) with 95% confidence interval. (B) Kaplan-Meier 
curve survival analyses of the LCI cohort stratified by AFP and BCLC staging with NDMT or Non-NDMTs. 
P value is from Mantel-Cox log rank analyses. (C) Time-dependent ROC curve analyses at two-years for 
Barcelona-Clinic Liver Cancer (BCLC), alpha-feto protein (AFP), BCLC + NDMT, or AFP + NDMT with 
associated AUCs. (D) Disease-free Kaplan-Meier survival analysis of the LCI and Korean cohort. (E) Odds ratio 
(±95% confidence interval) of logistic regression analyses of the LCI cohort.
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To investigate the genomic changes between the NDMT and Non-NDMT subtypes, we determined the 
most frequent somatic mutations and gene copy number alterations for each group, including known genes 
important for HCC progression (AZIN1, TERT, ARID2, and CDKN2A) in the TCGA-LIHC cohort (Fig. 3D). 
In the NDMT subtype, we observed TP53 is most frequently mutated at a frequency of 45% as compared to 
27% in the Non-NDMT subtype (Supplementary Fig. S3C,D). Consistently, TP53 mutations were more preva-
lent in the NDMT subtype compared to the Non-NDMT subtype in the LCI cohort (Supplementary Fig. S3B). 
The NDMT subtype had a CTNNB1 mutation frequency of 16% compared to 32% in the Non-NDMT sub-
type (Supplementary Fig. S3C,D). Notably, CDKN2A deletions are more prevalent in the Non-NDMT subtype 
compared to NDMT subtype. The gene signature showed no enrichment for MYC gene amplification for either 
subtype in both the TCGA-LIHC and LCI cohorts, indicating that the signature identified tumors with active 
NELFE/MYC signaling and not MYC amplification alone (Fig. 3C, Supplementary Fig. S3B,C).
Identification of the NDMT subtype in other tumor types. To assess the gene signature’s ability to 
predict NDMTs in other cancers, we analyzed data from five commonly occurring solid tumor types using the 
TCGA database. Datasets used for analyses included stomach adenocarcinoma (STAD), lung adenocarcinoma 
(LUAD), colon adenocarcinoma (COAD), prostate adenocarcinoma (PRAD), and invasive breast carcinoma 
(BRCA). In addition, we assessed Burkitt’s lymphoma (LYM) using the dataset from Hummel, et al., which con-
sists predominantly of lymphomas with MYC alterations24. Accordingly, the gene signature was predictive of OS 
in the STAD cohort (p < 0.001), COAD cohort (p = 0.044), and with near statistical significance in the LUAD 
cohort (p = 0.067) (Fig. 4A–C). In the Hummel cohort of 220 lymphoma cases, of which 80% had some form of 
MYC alteration, the gene signature identified the NDMT subtype with near statistical significance (p = 0.150) 
(Supplementary Fig. S4A)24. Consistent with Hummel et al., the NDMT subtype is significantly enriched in lym-
phoma samples with MYC alterations (Fisher’s exact test, adjusted p < 0.001), whereas the Non-NDMT sub-
type is significantly enriched with MYC-negative lymphoma samples (Fisher’s exact test, adjusted p = 0.021). 
Additionally, the gene signature is more robustly associated with a poor survival in HCC than other tumor types 
Figure 3. Genomic landscape of NDMTs. (A) Comparison of the NDMT tumor subtype to published 
signatures is indicated in the LCI cohort. Fisher’s exact test was performed to test for enrichment with 
Bonferonni correction (presented as adjusted p value). (B) (Left) Gene set enrichment analysis (GSEA) of 
differentially expressed genes (DEGs) between NDMTs vs. Non-NDMTs in both the LCI and TCGA-LIHC 
cohort (p < 0.001). Only genes the overlap of DEGs in both cohorts are shown. (Right) The overlap of DEGs in 
both HCC cohorts were analyzed using ENCODE to identify up-stream targets (right). Only DEGs in the top 
ten groups are shown. Light blue represents MYC signaling/targets. (C) Heatmap of NELFE/MYC target genes 
differentially expressed between NDMTs vs. Non-NDMTs (p < 0.001) in the LCI cohort. Student’s t-test was 
performed to identify DEGs following enrichment analysis for NELFE/MYC target genes. (D) Mutation and 
copy number alterations in the TCGA-LIHC cohort of the most frequently altered genes in HCC. % represents 
frequency of alterations for the entire cohort. Top graph represents frequency (%) of alterations per sample. 
Right side graph represents total number of alterations for specified gene.
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(Fig. 4D). Interestingly, in prostate and breast cancer, the gene signature did not classify tumors into the NDMT 
or Non-NDMT subtypes with statistical significance (Supplementary Fig. S4A,B). This is consistent with previous 
work as the most common alterations in prostate cancer are androgen-regulated promoter fusions with members 
of the E26 transformation-specific transcription factors. Furthermore, MYC and NELFE alterations are found in 
only 8% and 0.8% of prostate cancer patient samples, respectively25.
Discussion
The heterogeneous nature of cancer is related to the diverse etiologies associated with the individual disease, 
which is exemplified in HCC. In recent years, the discovery of targeted therapy has led to novel agents that act 
directly on signaling cascades important for tumor survival. Although some therapies have provided modest 
improvements, recent failures in the testing of systemic drugs for advanced cancers suggest a need for better 
patient stratification and novel therapies. In the current study, we developed a gene signature that could serve as a 
predictive marker of survival for HCC with an NDMT biology. Accordingly, we validated this signature through 
a range of racial/ethnic backgrounds and underlying etiologies. Varying etiologies of chronic liver disease con-
tribute to different signaling pathways that drive tumorigenesis and promote tumor heterogeneity, making treat-
ment difficult. However, our gene signature consistently predicted OS, indicating that the signature is a strong 
predictor of tumors with a NELFE/MYC biology associated with poor outcome. Since the signature consists of 
oncogenic MYC target genes regulated by NELFE, it is reasonable that the NDMT subtype consists of tumors that 
are stem-like, have dysregulated WNT signaling, and metastatic features5,26.
The systemic and locoregional therapies offer only marginal improvements in survival, liver transplantation 
and hepatic resection remain the gold standard for early HCC. However, the selection for curative therapy is 
based on physical features of the tumor, failing to recognize the underlying biology of the tumor27. In addition, 
there are currently many staging systems for HCC, most notably the BCLC and the AJCC/TNM 8th edition28. 
While TNM staging relies on accurate histopathologic diagnosis of both the tumor and local lymphatics, BCLC 
Figure 4. The NDMT gene signature identifies NDMTs in other epithelial tumor types. Kaplan-Meier curve 
of TCGA datasets (A) STAD: stomach adenocarcinoma (B) LUAD: lung adenocarcinoma (C) COAD: colon 
adenocarcinoma. P values are from Mantel-Cox log rank test. (D) Forest plot of hazard ratios (±95% CI) for OS 
at 5 years from all cancer types (Liver cancers: LIHC, KOR, LEC, and LCI; other cancers include LYM: Burkitt’s 
lymphoma, PRAD: prostate adenocarcinoma, BRCA: invasive breast carcinoma).
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stratifies patients based on liver function followed by the extent of disease. Recent studies have shown a lack of 
prognostic accuracy between pT3 and pT4 tumors, thus limiting TMN for late stage tumors. In addition, when 
tumors are staged using the BCLC classification, the subjective component of performance status and Child-Pugh 
criteria leads to selection bias, where the majority of patients are classified as BCLC stage B, making this an 
imperfect system28,29. Moreover, biomarkers such as AFP have been utilized to predict survival outcome, however, 
the results remain inconsistent. Recent work by Berry et al. implicate AFP levels > 320 ng/ml as an independent 
predictor of recurrence after transplantation30. Conversely, Farinati et al. found that 43% of patients with early 
HCC had normal AFP levels12. While AFP may be strongly correlated with advanced disease, there are clear 
shortcomings in early disease. Thus, the ability to identify tumors based on their biology, independent of AFP 
or BCLC staging, or in combination with BCLC staging, solidifies the NDMT as a prognostic tool with possible 
therapeutic value.
Multiple HCC gene signatures have been developed for translational application, including multiple pro-
liferation signatures, an early metastatic gene signature, a high risk cirrhotic signature, an inflammation/
immune response-related signature, and stem-like gene signatures; most of which are associated with poor out-
come10,18,19,31–36. While these signatures have potential for prognostication in HCC, none have been introduced 
into clinical practice. As evident in our analyses, all six gene signatures performed variably across different HCC 
cohorts. This is mostly due to the vast inter- and intra-tumor heterogeneity of HCC and the underlying etiolo-
gies associated with the tumor, including HBV/HCV, alcoholic- and non-alcoholic fatty liver disease. Moreover, 
the patients tested are predominantly Asians or Caucasians with at most three dominant etiologies, including 
HBV, HCV, or alcohol18. Most importantly, some signatures are predominantly developed using genes that are 
tumor-specific but not functionally inter-related and thus, ignores the tumor biology that drives HCC. The 
NDMT signature in contrast performed consistently across the three cohorts tested, suggesting that utilizing 
genes that are functionally important, such as the NELFE/MYC signaling pathway, may be better at identifying 
more homogeneous subtypes.
MYC alteration is found in more than 30% of HCC and its signaling can be altered without concomitant 
gene amplification or mutation3–5. Instead, its expression can be altered through upstream signal transduction, 
epigenetic changes and the regulation of mRNA or protein stability4,7. This is evident in HCC that are driven by 
NELFE, an RNA binding protein that can interact with MYC-associated mRNA targets or the MYC protein to 
directly promote MYC-induced tumorigenesis5. Moreover, NELFE is upregulated in 10–17% of HCC, whereas 
the dysregulation of any combination of NELFE, MYC, or NELFE/MYC makes up ~38% of HCC5. Although our 
gene signature did not identify MYC amplified tumors, given the extent to which both genes play an important 
role in HCC progression together or independently, the NDMT gene signature could serve as a predictive marker 
of survival for not only tumors driven by NELFE/MYC, but also MYC or NELFE driven tumors.
In conclusion, the NDMT gene signature is robust in identifying the NDMT subtype with the ability to add 
valuable prognostic information in HCC. Moreover, we demonstrated that the utility of the NDMT signature is 
not limited to HCC. MYC alteration is found in 21% of all TCGA samples across 33 different tumor types and 
NELFE is upregulated in most solid tumors4. When we tested our signature among five common cancers, we 
found that our gene signature can identify NDMTs in three of the six cancer types, including STAD, LUAD and 
COAD. These results suggest the signature identifies a functionally specific tumor type whose driver is NELFE/
MYC signaling. Furthermore, the signature is independent of previously established diagnostic tools such as 
TNM, BCLC and AFP. Future work will be needed to demonstrate the full breadth of the signature and its role 
in shaping therapeutic decisions. However, the NDMT would provide prognostic value across etiologies without 
complete pathologic staging and eliminate clinician bias, which may prove to be a valuable adjunct to the current 
staging systems.
Methods
Patient cohorts. Each HCC dataset is publicly available at the Gene Expression Omnibus (GEO; http://www.
ncbi.nlm.nih.gov/geo) or the TCGA (https://cancergenome.nih.gov/). The data for the Liver Cancer Institute 
(LCI) cohort (GSE14520), Laboratory of Experimental Carcinogenesis (LEC) (GSE1898 and GSE4024), and 
TCGA-LIHC are previously described10,13,14. For the Korean cohort data, we merged two independent datasets 
together to improve our prediction due to the low number of samples in each dataset. Accordingly, 88 HCC cases 
are from Keimyung University and Korea University and 90 cases are from Seoul National University Hospital 
(GSE15765)15,16.
The TCGA datasets (RNASeq and clinical tables) for gastric (STAD), lung (LUAD), colon (COAD), prostate 
(PRAD) and breast (BRCA) were downloaded (03-27-2015) using the R (v3.12) TCGA Assembler package, http://
www.compgenome.org/TCGA-Assembler)37. For the lymphoma cohort (LYM), data was downloaded through 
the Oncomine Research Edition database (https://www.oncomine.org/resource/login.html)24,38. To curate the 
TCGA-LIHC for BCLC staging, we used ECOG performance, tumor size, number and multi-nodularity, as well 
as Child Pugh score. All cases with incomplete data were not included.
Development of NDMT prognostic index. We previously identified 68 MYC associated genes that were 
also regulated by NELFE5. From the 68-gene list, we identified 20 genes that had at least a 1.5-fold change between 
tumor and non-tumor in HCC samples found in the LCI cohort. Log 2 expression values from the LCI cohort 
were transformed into z-score values followed by Survival Risk Prediction analysis (BRB Array Tools v.4.5.1)11. 
Using the 20 genes, survival risk prediction analysis was performed in the training LCI Cohort. Briefly, the algo-
rithm applies univariate Cox proportional hazards regression following principal components analysis, which 
transforms possible correlated variables into two principal components. The result of this algorithm are regres-
sion coefficients (weight) related to survival data for each gene in the training dataset. Next, the prognostic index 
score is calculated using the weighted average of the principal component values from the Cox regression from 
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the first step. Lastly, patients are then partitioned into two risk (high = NDMT, low = Non-NDMT) groups of 
equal size using the median as a cutoff. Kaplan–Meier curve analysis, 10-fold cross validation and 1000 permuta-
tions based on log rank statistic are performed to evaluate the accuracy of the score system. Because we wanted to 
ensure all 20 genes were used, the significance threshold of the Cox model was set to 0.999. For cross validation, 
the index score was calculated by summing the product of the expression level of a gene and its corresponding 
regression coefficient to determine if a new sample should be classified as NDMT (worse overall survival) or 
Non-NDMT tumor types (better OS). The prognostic index can be computed by the formula:
∑= − .PI w x 0 620546
i
i i
where wi and xi are the weight and logged gene expression for the i-th gene. The gene list and weight for each 
gene can be found in Supplementary Fig. S1. A new sample is predicted as NDMT (Non-NDMT) if its prognostic 
index (PI) is larger than (smaller than or equal to) −0.062139.
For all validation analyses, the log 2 expression values for each gene were transformed into z-score values, 
with the exception for the Burkitt’s lymphoma cohort, which was downloaded from Oncomine (https://www.
oncomine.org/resource/login.html) in z-score format. Level 3 RNASeq data from the TCGA were log 2 (log 2 + 1) 
transformed followed by z-score transformation using R (version 3.3.3). OS or recurrence was then analyzed 
using Kaplan-Meier and Cox regression analyses.
Statistical Analysis. In all statistical analyses for this study, a two-sided p-value of <0.05 is considered sta-
tistically significant. Clinical data was evaluated using Chi-squared test. For enrichment analysis, Fisher’s exact 
test was performed followed by Bonferroni correction to adjust for multiple hypothesis testing. Patient survival 
outcome was evaluated by using Kaplan-Meier analysis with Cox-Mantel log-rank test to determine statistical 
significance. Statistics were calculated using GraphPad Prism 7.0 (GraphPad, San Diego, CA). For heatmaps, we 
performed hierarchal clustering analyses with Pearson correlation Ward linkage.
Univariate and multivariate analyses was performed with Cox proportional hazards regression analysis using 
STATA 14.0 (College Station, TX). The association between each clinical variable and survival outcome was first 
evaluated with univariate analysis followed by multivariate analysis, which included clinical variables with a 
p-value < 0.05 in the univariate analysis. Tumor size was not used in multivariate analyses because it was already 
used to determine tumor stage. No multi-collinearity of covariates was found, and the proportional hazards 
assumption was met in the final models.
Nearest Template Prediction (NTP) was used for gene signature determination (not including the NDMT 
signature) across all HCC cohorts, we used Nearest Template Prediction algorithm23 with R package CMScaller39. 
In short, a set of genes is used as a template to define different classes of biological samples, then the samples are 
categorized based on the provided gene set, and finally prediction confidence is calculated based on resampling 
technique. The liver cancer signatures used for the comparison were Hepatoblastoma signature13, EpCAM signa-
ture20, Wnt-TGFB and MYC signatures21 and Metastasis signature10. All gene expression values from each cohort 
were log2- and z-transformed before NTP analyses.
Time-dependent ROC calculation: Performance of multiple gene signatures based on gene expression from 
tumor cells were compared by using two-year time-dependent receiver operating characteristics (ROC) from 
censored data (Heagarty et al., 2000) with R package survivalROC (https://cran.r-project.org/web/packages/sur-
vivalROC/index.html). The time-dependent ROC algorithm used in this study is cumulative sensitivity, which 
calculates probability of a patient that will have a certain outcome (in this case the outcome is death) before a spe-
cific time, and dynamic specificity, which calculate the probability that a patient has a certain marker value (such 
as risk score or class status) less than or equal to a certain threshold after a certain time. In this study we chose 
cumulative sensitivity and dynamic specificity because we specifically defined two different time points for evalu-
ation as two- and five-year periods. The survival estimator used in this calculation is Kaplan-Meier estimator. For 
the NDMT signature, the marker used in the time-dependent ROC was the prognostic index values. For all other 
signatures, the marker used was the distance measures from the signature of interest. 95% confidence interval 
calculation was performed by using 1,000 iteration of ordinary bootstrap method with R package.
Heatmaps of NDMT vs Non-NDMT from the LCI and TCGA-LIHC cohorts were generated by ComplexHeatmap 
R package. The genes presented in the heatmaps represent differentially expressed genes (Student’s test with FDR 
via Benjamini-Hochberg, adjusted p-value p < 0.00001) between NDMT vs Non-NDMTs and fold-change >1.4 or 
<0.714.
Data Availability
The datasets generated during or analyzed during the current study are available from the corresponding authors 
upon reasonable request.
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